Disruption of glutamine carrier Slc38a1 causes cognitive impairment, anxiety and depressive-like behavior
GABAergic deficit is associated with key neuropsychiatric disorders, such as major depressive disorder (MDD), anxiety, schizophrenia, and autism spectrum disorder (ASD). However, it is not known whether these disorders are causal to or a result of GABAergic dysfunction. We previously showed that the Solute carrier 38 member 1 (Slc38a1) accumulates glutamine in subpopulations of GABAergic neurons and sustains neurotransmitter GABA synthesis. Genetic inactivation of Slc38a1 in mice caused lowered GABA levels, altered synaptic vesicle morphology, slowed {gamma}-oscillations, and reduced cortical processing and plasticity, selectively at GABAergic synapses. We now demonstrate a significant reduction in learning and memory performance in the Morris water maze and increased signs of despair in the forced swim test in Slc38a1-/- mice compared to Slc38a1+/+ mice, implicating cognitive impairments and depressive-like behavior. Examination in the open field maze also indicates anxiety and/or reduced interest in exploration. There are no signs of impaired sociability or recognition of social novelty in the three-chambered test, speaking against involvement in schizophrenia- or ASD-like disorders. Metabolic phenotyping and measurement of the locomotion do not segregate the Slc38a1 genotypes, suggesting that the cognitive impairments, depressive-like behavior and anxiety are brain-dependent. Our data is further supported by a pathologic variant of Slc38a1 in a family with depression and suicidal behavior. Altogether, we demonstrate that dysfunction of Slc38a1-dependent GABA synthesis and the ensuing impaired {gamma}-oscillations underpin the pathogenesis of neurocognitive deficits, anxiety and depression.